CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

Cellular immune responses have the potential to elicit dramatic and sustained clinical remissions in lymphoma patients. Recent clinical trial data demonstrate that modification of T cells with chimeric antigen receptors (CARs) is a promising strategy. T cells containing CARs with costimulatory domai...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Till, Brian G., Jensen, Michael C., Wang, Jinjuan, Qian, Xiaojun, Gopal, Ajay K., Maloney, David G., Lindgren, Catherine G., Lin, Yukang, Pagel, John M., Budde, Lihua E., Raubitschek, Andrew, Forman, Stephen J., Greenberg, Philip D., Riddell, Stanley R., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3350361/
https://ncbi.nlm.nih.gov/pubmed/22308288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-10-387969
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados